New Analysis of Phase 3 study presented at SUO 2020

New Data Analyses from Phase 3 Study of Investigational Gene Therapy Nadofaragene Firadenovec Presented at Society of Urologic Oncology Annual Meeting Adds More Evidence to Data Published in Lancet Oncology Low rate of cystectomy and delayed time to cystectomy among...

FerGene Appoints Top Biotech Leaders to Executive Team

Gene therapy company focused on uro-oncology continues to expand operations and prepare for the future commercialization of an investigational treatment for non-muscle invasive bladder cancer CAMBRIDGE (June 17, 2020) – FerGene, Inc., a privately held gene therapy...

FerGene Provides Update on BLA for Nadofaragene Firadenovec

The U.S. Food and Drug Administration (FDA) has issued a response to the Biologics License Application (BLA) for investigational gene therapy, nadofaragene firadenovec, which was submitted by FKD Therapies Oy, the company leading the development and regulatory filing...

FerGene Appoints David Meek Chief Executive Office

CAMBRIDGE, Mass. – December 19, 2019 FerGene, a new gene therapy company launched by Ferring Pharmaceuticals and Blackstone Life Sciences in November, today announced the appointment of David Meek as President and Chief Executive Officer, effective January 14,...